Black Book Research Identifies Top Global Growth Opportunities for openEHR Adoption in 2025

March 31, 2025 7:00 AM

As global healthcare systems accelerate digital transformation and demand for AI-ready, longitudinal clinical records grows, openEHR is emerging as a pivotal solution. In its Q1 released 2025 Global Market Insight Report, Black Book Research identifies the countries best positioned to drive rapid adoption and national expansion of openEHR-the vendor-neutral, open-standard framework enabling scalable, interoperable health data infrastructure. The...

Read more

Empowering Research: Sirius Fine Chemicals Boosts Product Credibility With Bioz AI-Driven Citation Badges

March 31, 2025 4:00 AM

Bioz, Inc., the AI-driven citation management leader, is showcasing its new partnership with Sirius Fine Chemicals SiChem GmbH, a well-recognized supplier of high-quality chemical reagents and specialty compounds. Through the integration of Bioz Badges, SiChem is leveraging AI-driven technology to display peer-reviewed citations that validate the impact of its products in published scientific literature.Advanced Bioz Prime Badges seamlessly...

Read more

Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

March 31, 2025 2:00 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 31 March 2025 consists of 4,093,539 ordinary shares of 1p each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 4,093,539.The figure of 4,093,539 ordinary shares may be used by shareholders of the...

Read more

DEA Forces Marijuana Pharma Drug Industry Offshore: A Symbol of DEA Systemic Obstruction Against Trump Administration Directives

March 30, 2025 6:00 AM

As the Trump administration pushes to reshore pharmaceutical manufacturing through aggressive tariffs and trade policies, a less visible but equally critical challenge persists: the Drug Enforcement Administration's (DEA) stringent regulations. Critics argue that the agency's bureaucratic delays and restrictive oversight are not only hindering medical research but also driving pharmaceutical companies overseas , undermining domestic...

Read more

CPC Announces Semaglutide Significantly Improves Walking Distance, Symptoms and Quality of Life for People with PAD and Diabetes

March 29, 2025 11:15 AM

A novel study of a semaglutide, a glucagon-like peptide-1 (GLP-1) agonist used to treat type 2 diabetes, obesity and cardiovascular disease, semaglutide was found to significantly improve maximal walking distance in people with symptomatic peripheral artery disease (PAD) and type 2 diabetes, meeting the study's primary endpoint. The STRIDE Trial, presented at the American College of Cardiology's Annual Scientific Session (ACC.25), is the first...

Read more

Regulatory Condition Satisfied for License Agreement between AbbVie and Gubra

March 28, 2025 6:20 PM

HØRSHOLM, DK / ACCESS Newswire / March 28, 2025 / Gubra (CPH:GUBRA)With reference to AbbVie's (NYSE:ABBV) and Gubra A/S' (CPSE:GUBRA) joint announcement of March 3, 2025 regarding a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity, the US Federal Trade Commission today granted early termination of the waiting period under the HSR Act.Closing of the license agreement remains...

Read more

Scott Stringer Named Chairman of the Board at the National Children’s Cancer Society

March 28, 2025 5:00 PM

The National Children's Cancer Society (NCCS) is proud to announce Scott Stringer as its newest Chairman of the Board. A longtime advocate for children and families battling cancer, Scott brings decades of experience, dedication, and passion to the role. He has served previously as Chairman and is excited to take on this role once more."It is an honor to have the opportunity to work more closely with the talented staff, as well as our dedicated...

Read more

The Future of Physical Therapy: Trends to Watch in 2025 and Beyond

March 28, 2025 11:00 AM

Since the immerge of healthcare innovation and technology, there has been significant change that's complementing the future of Physical therapy. This year, there is a boost in personalized physical therapy, easing the therapeutic service to patients to be more accessible & effective. A new era of patient care is evolving with the help of AI intersecting with telehealth & wellness programs. Technology is now providing the patient with effective...

Read more

PointClickCare and VistaRx Announce Joint Solution That Solves Incorrect Billing in Long-Term Care

March 28, 2025 10:00 AM

PointClickCare, a leading healthcare technology platform enabling meaningful collaboration across the care continuum, and VistaRx, a health-tech company that develops solutions that simplify pharmacy data management and revenue capture, announced a new partnership to prevent incorrect billing due to gaps in resident coverage data in long-term care (LTC) facilities and pharmacies.This new service, called Clean Bill, will enable PointClickCare...

Read more

Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern

March 28, 2025 9:15 AM

Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"),has reported its financial and operational results for the fourth quarter and year ended December 31, 2024.Fourth Quarter and Full Year 2024 Financial ResultsThe company's strong balance sheet and overall progress enabled it to remove its Material Uncertainty Related to Going Concern. Management is confident that there is sufficient working capital as...

Read more

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

March 28, 2025 9:00 AM

Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced the results of a new survey of 27 board certified veterinary oncologists practicing in the U.S. regarding Canalevia-CA1 and the treatment of chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1, the company's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug product for the treatment of CID...

Read more

UniDoc Completes Purchase of AGNES Connect(R) Software from AMD Telemedicine

March 28, 2025 9:00 AM

UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company"), announces that, further to its news release dated March 19, 2025, it has closed the acquisition of the AGNES Connect software from AMD Telemedicine ("AMD")."The AGNES Connect software forms the foundation of UniDoc's NEIL Connect software platform, and I am excited to complete this acquisition and bring the ownership and future development of this software in...

Read more

Global Healthcare Faces Unprecedented Cybersecurity Crisis: Black Book Research Reveals Top 10 Countries at Highest Risk

March 28, 2025 8:00 AM

Black Book Market Research, a leading independent and unbiased technology survey organization, today unveiled alarming results from its comprehensive Q1 2025 Global Healthcare Cybersecurity Survey. Engaging over 1,200 healthcare administrators sourced through LinkedIn professional groups worldwide, the study highlights a stark increase in cybersecurity threats to electronic health records (EHRs) and patient data, significantly affecting...

Read more

International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award

March 28, 2025 6:00 AM

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that International Medication Systems, Ltd. ("IMS"), a subsidiary of Amphastar Pharmaceuticals, Inc. ("Amphastar") received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration ("FDA"). This prestigious award recognizes IMS significant efforts in preventing and alleviating critical drug shortages, ensuring that patients have access to essential medications.IMS...

Read more

Bionic Bloom to Host Live 5-MeO-DMT Integration Session

March 28, 2025 5:00 AM

Bionic Bloom, the nation's first legal psilocybin therapy center and a leader in psychedelic-assisted care, is proud to announce a groundbreaking on-stage presentation at Cannadelic Miami 2025. As Title Sponsor of the world's largest cannabis and psychedelics conference, Bionic Bloom will offer attendees a rare, front-row experience: a live integration session from its cutting-edge 5-MeO-DMT clinical trials.The session will be conducted on Day 2...

Read more

Genflow Biosciences PLC Announces Holding in Company

March 28, 2025 3:10 AM

1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason for NotificationAn acquisition or disposal of voting rights3. Details of person subject to the notification obligationNameMR ERIC LEIRECity of registered office (if applicable)15 Ingestre Place,Country of registered office (if applicable)UKNameCity of registered officeCountry of registered officeEric Leire 4. Details of the shareholderFull name of...

Read more

Genflow Biosciences PLC Announces Director Dealings

March 28, 2025 3:00 AM

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") the only longevity company listed in Europe, is pleased to announce that it has been notified that Dr. Eric Leire, CEO of the Company, has today purchased 2,100,000 ordinary shares in the Company at a price of 1.15 pence each on the open market.Details of the transaction are set out below:NameDr. Eric LeirePositionChief Executive OfficerDate of Purchase27 March...

Read more

IRLAB Provides Additional Efficacy Data from the Phase IIb Study of Pirepemat in Patients with Parkinson's Disease

March 28, 2025 2:20 AM

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, March 28, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson's disease, today announces further results based on prespecified in-depth efficacy analyses of the data generated in the Phase IIb dose finding and efficacy study of pirepemat (REACT-PD). The analysis reveals that in a medium plasma concentration...

Read more

Manzo Eye Care Announces Strategic Partnerships to Deliver Eye Test Equipment to Eye Care Professionals

March 28, 2025 1:46 AM

Manzo Eye Care is a leading provider of affordable and high-quality eye testing equipment. They are excited to announce new partnerships. They are teaming up with well-known industry leaders Haag Streit, iCare, and Nidek.Manzo Eye Care dedicates itself to providing advanced and reliable eye testing solutions. We are partnering with optometrists and eye care professionals across the country."At Manzo Eye Care, we support optometrists and eye care...

Read more

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

March 27, 2025 8:15 PM

Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 4,834,470 shares of the Company's common stock, having exercise prices of $1.58 and $4.91 per share, issued...

Read more